天宇股份股价下跌1.65% 原料药获欧洲CEP认证

Core Viewpoint - Tianyu Co., Ltd. has received CEP certification for its raw material drug, Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk, allowing it to sell in European markets and other regions that recognize the certification [1] Company Overview - As of August 12, 2025, Tianyu Co., Ltd. stock price is 29.28 yuan, down 1.65% from the previous trading day [1] - The company reported a trading volume of 464 million yuan and a turnover rate of 7.50% on the same day [1] - Tianyu Co., Ltd. specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations, covering treatment areas such as hypertension, hyperlipidemia, and diabetes [1] Financial Flow - On August 12, the net outflow of main funds was 24.54 million yuan, while the net inflow over the past five days was 11.32 million yuan [1]